Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials

Innate Immunity in Allergic Asthma

NCT06068335
Recruiting
Conditions Asthma
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to determine whether a potential type 2 signature, obtained through stimulation of cell lines with various allergens in vitro, correlates with an allergic or asthmatic disease state ex vivo. This type 2 signature will be multi-hierarchical in nature and will be comprised cell surface receptor expression, pathway activation, and gene upregulation.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Primary Outcomes

  • To determine which parameters of the established type-2 signature obtained in vitro is significantly different between healthy controls, allergic individuals, and asthmatic individuals ex vivo. (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2021-10-18
Completion: 2025-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Central Florida
Principal Investigators:
  • Justine T Tigno-Aranjuez, PhD (PRINCIPAL_INVESTIGATOR) - University of Central Florida
Contact Information
Study Contact:
Amoy Fraser, PhD, CCRP, PMP
4072668742
amoy.fraser@ucf.edu
Erica Martin, B.S.
4072668742
erica.martin@ucf.edu
Interventions
N/A
Study Locations (1 sites)
University of Central Florida, Orlando, Florida 32816 United States
Eligibility Criteria
Inclusion Criteria: * Participants must be at least 18 years of age * no history of allergic disease (healthy controls), have clinically diagnosed allergies, or have clinically diagnosed asthma. Exclusion Criteria: * Pregnant women and prisoners will be excluded from the study. * Individuals currently suffering from any acute infections and those known to suffer from light-headedness will be excluded.
Conditions Severe Asthma
Phase PHASE2
Enrollment 512
Locations 14 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) Over a 12-Week Treatment Period in Patients With Severe Asthma Not Controlled With Medium to High Dose ICS/LABA

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Frevecitinib — Frevecitinib (KN-002) delivered via a dry powder inhaler (DPI)
  • Drug: Placebo — Matching placebo to frevecitinib

Primary Outcomes

  • Pre-BD FEV1 (Week 12)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-07-16
Completion: 2027-11-30
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 512 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Kinaset Therapeutics Inc
Contact Information
Study Contact:
Kinaset investigative site
855-818-2289
Research site
Kinaset investigative site
855-818-2289
Research site
Kinaset investigative site
855-818-2289
Research site
Interventions
  • Drug: Frevecitinib — Frevecitinib (KN-002) delivered via a dry powder inhaler (DPI)
  • Drug: Placebo — Matching placebo to frevecitinib
Study Locations (14 sites)
Research site, Lancaster, California 93534 United States
Research site, San Jose, California 95117 United States
Research site, Brandon, Florida 33511 United States
Research site, Miami, Florida 33137 United States
Research site, Tampa, Florida 33607 United States
Research site, Chicago, Illinois 60612 United States
Research site, Kansas City, Missouri 66160 United States
Research site, Charlotte, North Carolina 28277 United States
Research site, Pittsburgh, Pennsylvania 15213 United States
Research site, Rock Hill, South Carolina 29732 United States
Eligibility Criteria
Inclusion Criteria: Capable of understanding the written informed consent, provides signed and witnessed written informed consent prior to any study-related procedures, and agrees to comply with protocol requirements. Body mass index between 18 to 40 kg/m2 and weight ≥40 kg at screening. Documented physician-diagnosed asthma for at least 12 months prior to screening. Has received a physician-prescribed asthma controller regimen with medium dose or high dose ICS plus LABA, with or without additional controller medications for at least 6 months prior to screening and the dose of ICS and additional controller(s) must be stable for at least 4 weeks prior to screening and throughout the screening/run-in period. Has a pre-bronchodilator FEV1 value of ≥40% and ≤80%, predicted, at screening and at Day 1. Has a post-bronchodilator reversibility of FEV1 ≥12% and ≥200 mL documented during screening (15 to 30 min after administration of 4 puffs of albuterol/salbutamol). Has an ACQ-6 score of ≥1.5 during screening (ie, Visit 1 and Visit 2). Has a documented history of at least 1 asthma exacerbation in the 12 months prior to the screening visit, while using medium to high dose ICS/LABA therapy Acceptable inhaler, peak flow meter, and spirometry techniques during the screening/run-in period. ≥80% compliance with required use of the ePRO device within the last 14 days of the screening/run-in period. Females of childbearing potential who are sexually active with a non-sterilized male partner must use a highly effective method of contraception from the time informed consent is obtained and must agree to continue using such precautions throughout the study and continue using such precautions for 16 weeks after the final dose of study treatment. Exclusion Criteria: Current smokers or participants with a smoking history of ≥10 pack years Participants with a current history of angina or history of myocardial infarction, stroke, or TIAs within the past 12 months from screening are disallowed. Participants with a history of pulmonary embolic or thrombotic events, or genetic or autoimmune (eg anti-phospholipid syndrome) predisposition for thrombosis are disallowed. Any concomitant respiratory disease that, in the opinion of the investigator and/or medical monitor, will interfere with the evaluation of the investigational product or interpretation of participant safety or study results Any clinically relevant abnormal findings in hematology, clinical chemistry, coagulation, or urinalysis (laboratory results from visit), physical examination, vital signs during the screening/run-in period which, in the opinion of the investigator, may put the participant at risk because of his/her participation in the study Evidence of active liver disease including jaundice or AST, ALT, or bilirubin greater than twice the upper limit of normal. History of cancer Participants with a respiratory tract infection that has not fully resolved by screening, or who experience an RTI during screening or at Day 1. Evidence of a clinically significant infection or receiving treatment with systemic antibiotic, anti-parasitic, or antiviral medications at Day 1. Known history of active TB or a positive QFT-G test for TB during screening. A positive hepatitis B surface antigen, or hepatitis C virus antibody serology at screening, or a positive medical history for hepatitis B or C. A positive human immunodeficiency virus test at screening or participant taking antiretroviral medications, as determined by medical history and/or participants verbal report. History of sensitivity to any component of the investigational product formulation or a history of drug or other allergy that, in the opinion of the investigator or medical monitor contraindicates their participation. Use of oral or topical JAK inhibitors for any reason or use of immunosuppressive medication (eg, methotrexate, troleandomycin, oral gold, cyclosporine, azathioprine, intramuscular long-acting depot glucocorticoid, or any experimental anti-inflammatory therapy) within 3 months prior to screening and throughout the study. Receipt of any investigational nonbiologic agent within 30 days or 5 half-lives prior to screening, whichever is longer and throughout the study. Prescription of regular daily oral corticosteroids within 4 weeks prior to screening or during the screening/run-in period and throughout the study. Systemic glucocorticoid burst including taper within 15 days prior to screening or during the screening/run-in period and throughout the study. Prescription of concomitant parenteral monoclonal antibody therapy for the management of asthma or any other condition within a specified period prior to the screening visit Pregnant, breastfeeding, or lactating females. History of chronic alcohol or drug abuse within 12 months prior to screening, as determined by the investigator. Planned surgical procedures requiring general anesthesia or in-patient status for \>1 day during the conduct of the study. Receipt of any live or attenuated vaccines within 15 days prior to screening. Participants who have undergone bronchial thermoplasty. Prolonged QTcF \>470 ms at screening or baseline.
Conditions Premenstrual Dysphoric Disorder (PMDD)
Phase PHASE4
Enrollment 288
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

Premenstrual dysphoric disorder (PMDD) is a severe affective disorder impacting millions of women worldwide, thought to be due to altered sensitivity to hormone fluctuations across the menstrual cycle. Neuroactive steroid hormones (NAS) and the gamma-aminobutyric acid (GABA)-A receptor (GABAAR) are thought to play a role in PMDD. This research will assess the blood levels of GABAergic NAS, expression of associated enzymes, and expression of GABAAR subunits across the premenstrual (luteal) phase of the menstrual cycle in healthy controls and individuals with PMDD. Within the PMDD group, the investigators will assess how these measures are affected by a low-dose antidepressant medication versus placebo. The results will provide a comprehensive view of the changes in these systems across the menstrual cycle and will add to the investigator's understanding of the mechanisms that underlie PMDD, as well as therapeutic mechanisms of PMDD treatment.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: sertraline 50 mg daily — The intervention will be in the form of an oral pill, taken daily, from the day of positive urine ovulation test result until the day of menses onset.
  • Drug: Placebo Oral Tablet — The placebo oral tablet will be of the same shape, color, and manufacturer as the sertraline 50 mg oral tablets. Tablet will be taken daily, from the day of positive urine ovulation test result until the day of menses onset.

Primary Outcomes

  • Neuroactive Steroid Levels (Post ovulation up to 2 days, up to 5 days pre-menses prediction)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-05-14
Completion: 2029-07-01
Eligibility
Age: 18 Years – 50 Years
Sex: FEMALE
Volunteers: true
Enrollment: 288 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Johns Hopkins University
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Liisa Hantsoo, PhD (PRINCIPAL_INVESTIGATOR) - Johns Hopkins University
Contact Information
Study Contact:
Victoria Paone, B.S.
4436854258
vpaone1@jh.edu
Victoria Seo, B.S.
vseo1@jh.edu
Victoria N Paone, B.S.
443-685-4258
vpaone1@jh.edu
Reproductive Mental Health Center
Interventions
  • Drug: sertraline 50 mg daily — The intervention will be in the form of an oral pill, taken daily, from the day of positive urine ovulation test result until the day of menses onset.
  • Drug: Placebo Oral Tablet — The placebo oral tablet will be of the same shape, color, and manufacturer as the sertraline 50 mg oral tablets. Tablet will be taken daily, from the day of positive urine ovulation test result until the day of menses onset.
Study Locations (2 sites)
Reproductive Mental Health Center, Baltimore, Maryland 21205 United States
University of Virginia, Charlottesville, Virginia 22903 United States
Eligibility Criteria
Inclusion Criteria: * female sex, * fluent in the English language * regular menstrual cycles (24-35 days) * age 18-50 years old * ability to give written informed consent Exclusion Criteria: * psychiatric medication use in the past 2 months * substance use disorder in the past 6 months * lifetime history of psychotic disorder including schizophrenia * schizoaffective disorder, major depression with psychotic features * history of psychiatric disorder other than PMDD in past year * active suicidal ideation with plan or attempt in past 6 months * steroid hormone or hormonal contraceptive use (except levonorgestrel as emergency contraceptive) in past 2 months * pregnancy in past 6 months * history of brain injury * current or history of endocrine disorder including uncontrolled diabetes or thyroid disease * BMI\>40 * History of arrythmias, severe liver impairment, history of seizure disorder * If currently taking the following meds: methylene blue, linezolid * Other prohibited concomitant meds are Monoamine oxidase inhibitors (MAOIs), pimozide, and disulfiram
Conditions Major Depression Disorder
Phase NA
Enrollment 198
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this multicentric randomized controlled trial is to compare the effectiveness and safety of home-based tDCS for the treatment of major depression versus tDCS treatment in a healthcare centre, and explore the effects of an accelerated home-tDCS protocol. The change in depression index at the end of treatment, measured with MADRS, will be the primary outcome.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Device: Accelerated protocol of home Transcranial direct current stimulation — Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique in which a weak direct current (2 mA) is applied to the scalp via electrodes. The anode will be applied to F3 (the dorsolateral prefrontal cortex) and the cathode to F8 (the contralateral frontotemporal region). The application of tDCS will be carried out at home in this group. Each session will consist of 20 minutes of stimulation. Dose: 3 weeks, daily. (1) 1st week - 3 times per day; (2) 2nd Week - 2 times per day; (3) 3rd week - 1 time per day (total of 42 sessions).
  • Device: Conventional protocol of home Transcranial direct current stimulation — Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique in which a weak direct current (2 mA) is applied to the scalp via electrodes. The anode will be applied to F3 (the dorsolateral prefrontal cortex) and the cathode to F8 (the contralateral frontotemporal region). The application of tDCS will be carried out at home in this group. Each session will consist of 20 minutes of stimulation. Dose: 9 weeks, from Monday to Friday. 1 time per day (total of 42 sessions).
  • Device: Conventional protocol of in person Transcranial direct current stimulation — Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique in which a weak direct current (2 mA) is applied to the scalp via electrodes. The anode will be applied to F3 (the dorsolateral prefrontal cortex) and the cathode to F8 (the contralateral frontotemporal region). The application of tDCS will be carried out at the medical facilities. Each session will consist of 20 minutes of stimulation. Dose: 9 weeks, from Monday to Friday. 1 time per day (total of 42 sessions).

Primary Outcomes

  • MADRS (End of treatment: 3 week for Accelerated home-tDCS arm; 9 week for Conventional home-tDCS and ambulatory tDCS arm.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-14
Completion: 2027-12-31
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 198 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ionclinics & Deionic SL
Collaborators: Hospital Universitari de Bellvitge, Consorci Sanitari del Maresme. Hospital Universitari de Mataró, Parc Taulí Hospital Universitari
Principal Investigators:
  • Ane Miren Gutiérrez Muto (STUDY_DIRECTOR) - Ionclinics & Deionics S.L.
  • Mar Hernández Secorún (STUDY_CHAIR) - Ionclinics & Deionics S.L.
  • Gustavo Sarriá Córdoba (STUDY_CHAIR) - Ionclinics & Deionics S.L.
Contact Information
Study Contact:
Ane Miren Gutiérrez Muto, PhD
+34960606200
investigacion@ionclinics.com
Ensayos Ionclincs
+34674059324
ensayos@ionclinics.com
Ionclinics
+34674059324
ensayos@ionclinics.com
Hospital Universitario de Bellvitge
Interventions
  • Device: Accelerated protocol of home Transcranial direct current stimulation — Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique in which a weak direct current (2 mA) is applied to the scalp via electrodes. The anode will be applied to F3 (the dorsolateral prefrontal cortex) and the cathode to F8 (the contralateral frontotemporal region). The application of tDCS will be carried out at home in this group. Each session will consist of 20 minutes of stimulation. Dose: 3 weeks, daily. (1) 1st week - 3 times per day; (2) 2nd Week - 2 times per day; (3) 3rd week - 1 time per day (total of 42 sessions).
  • Device: Conventional protocol of home Transcranial direct current stimulation — Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique in which a weak direct current (2 mA) is applied to the scalp via electrodes. The anode will be applied to F3 (the dorsolateral prefrontal cortex) and the cathode to F8 (the contralateral frontotemporal region). The application of tDCS will be carried out at home in this group. Each session will consist of 20 minutes of stimulation. Dose: 9 weeks, from Monday to Friday. 1 time per day (total of 42 sessions).
  • Device: Conventional protocol of in person Transcranial direct current stimulation — Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique in which a weak direct current (2 mA) is applied to the scalp via electrodes. The anode will be applied to F3 (the dorsolateral prefrontal cortex) and the cathode to F8 (the contralateral frontotemporal region). The application of tDCS will be carried out at the medical facilities. Each session will consist of 20 minutes of stimulation. Dose: 9 weeks, from Monday to Friday. 1 time per day (total of 42 sessions).
Study Locations (3 sites)
Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat, Barcelona 08304 Spain
Hospital Universitari de Mataró, Mataró, Barcelona 08304 Spain
Parc Taulí Hospital Universitari, Sabadell, Barcelona 08208 Spain
Eligibility Criteria
Inclusion Criteria: * Spanish or Catalan speakers of both sexes between the ages of 18 and 65. * Patients diagnosed with major depression, based on the criteria in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Specifically, patients will be included who meet the criteria for a major depressive episode with a longitudinal diagnosis of major depressive disorder, single or recurrent episode; or bipolar disorder type 1 or 2. Patients must obtain a moderate or higher score, therefore we establish a lower limit of 15 points on the Montgomery-Åsberg Depression Rating Scale (MADRS) (Alonzo et al., 2019). * Patients receiving or not receiving pharmacological treatment for depression will be included, and this will be recorded as an additional variable. * Have the ability and willingness to commit to the study team for supervision of the intervention sessions and close monitoring of safety. * Demonstrate the acquisition of the ability to properly apply home tDCS independently or with the help of a companion. Exclusion Criteria: * Patients with psychotic, schizoaffective, or personality disorders (both cluster A and B). * Patients with a history of neurological disease, intellectual disability, or cognitive impairment (inability to understand instructions or operate equipment). * Any exclusion criteria established by clinical guidelines on non-invasive brain stimulation (Woods et al., 2016): metal implants or head injuries, any electronic devices such as cochlear implants or cardiac pacemakers. Brain stimulation in the last 6 months. Clinical or family history of epilepsy. * Patients with dermatological problems, such as an allergic skin reaction at the electrode site. * High risk of suicide. Assessed through an interview with a psychiatrist and the use of the Spanish-validated Columbia Suicide Risk Scale (C-SSRS) (Al-Halabí et al., 2016). * Drug or alcohol abuse during the study or in the previous 3 months (except for nicotine). * Changes in pharmacological or non-pharmacological treatment (such as structured psychotherapy) during the study or in the 3 months prior to starting the trial. * Pregnancy.
Conditions Bipolar Disorder and Major Depressive Di...
Phase NA
Enrollment 180
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

Bipolar disorder (BD) are common psychiatric disorders often misdiagnosed, leading to delayed treatment. Even during stable phases, individuals with bipolar disorder experience residual cognitive impairments that affect their social functioning and quality of life. This study aims to explore social cognition deficits (e.g., emotional processing, theory of mind, attribution bias) and their relationship with executive functions (e.g., flexibility, inhibition, working memory) and memory in bipolar disorder and major depressive disorder, ultimately seeking to improve understanding of their functional outcomes. Social cognition and executive functions in BD are both state- and trait-related. One recent meta-analysis demonstrated impairment in social cognitive domains for manic, depressive, and euthymic bipolar disorders' patients but it remains unclear whether these social cognitive deficits in BD are due to executive functions and/or other confounding effects. Few studies have investigated the interdependency between these cognitive impairments in these two affective disorders while a better understanding of the link between executive functions and social cognition seems crucial in order to better characterize the nature of patients' deficits and thus their caring.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Behavioral: Analysis of social cognition, memory functioning, and executive functioning processes — Investigation of social cognition, memory functioning, and executive processes using a comprehensive clinical and cognitive assessment

Primary Outcomes

  • Social cognition: facial emotion recognition (Day 0)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-07
Completion: 2028-02-07
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: true
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: CHU de Reims
Collaborators: Public Mental Health Institution of the Marne
Contact Information
Study Contact:
Arthur KALADJIAN
03 26 78 70 45
kaladjiana@epsm-marne.fr
Sarah BARRIERE
03 26 78 70 45
barrieres@epsm-marne.fr
Damien JOLLY
326788472
djolly@chu-reims.fr
Chu Reims
Interventions
  • Behavioral: Analysis of social cognition, memory functioning, and executive functioning processes — Investigation of social cognition, memory functioning, and executive processes using a comprehensive clinical and cognitive assessment
Study Locations (1 sites)
Chu Reims, Reims, 51092 France
Eligibility Criteria
Inclusion criteria: * Patients between 18 and 65 years old, men or women * Having a diagnosis of bipolar disorder or depressive disorder * No substantial change in treatment for 2 weeks preceding study enrollment * Being a native French speaker * Patients enrolled in the national healthcare insurance program * Consenting to participate to the study Exclusion criteria: * The presence of any alcohol use disorder or any other substance use disorder in the last six months, except for tobacco dependence * A significant general medical illness, including neurological disorders or head trauma * A sensorial impairment uncorrected (visual and/or hearing) Group 3: First-degree relatives of bipolar patients Inclusion criteria: * Participants between 18 and 65 years old, men or women * Participants having at least one first-degree relative presenting an bipolar disorder (parents, children, siblings) * Being a native French speaker * Patients enrolled in the national healthcare insurance program * Consenting to participate to the study Exclusion criteria: * A diagnosis of schizophrenia or of bipolar disorder or of depressive disorder according to DSM-5 criteria * The presence of any alcohol use disorder or any other substance use disorder in the last six months, except for tobacco dependence * A significant general medical illness, including neurological disorders or head trauma * A sensorial impairment uncorrected (visual and/or hearing) Group 4, 5, 6: Healthy control participants Inclusion criteria: * Participants between 18 and 65 years old, men or women * Being a native French speaker * Patients enrolled in the national healthcare insurance program * Consenting to participate to the study Exclusion criteria: * A diagnosis of schizophrenia or of bipolar disorder or of major depressive disorder according to DSM-5 criteria * The presence of any alcohol use disorder or any other substance use disorder in the last six months, except for tobacco dependence * Participants having one first-degree relative presenting an bipolar disorder or depressive disorder or schizophrenia according to DSM-5 criteria * A significant general medical illness, including neurological disorders or head trauma * A sensorial impairment uncorrected (visual and/or hearing)
Conditions Depression Symptoms, Anxiety Symptoms
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

Therapists at the Grand Bahama Resilience Center (GBRC) will be trained to deliver Problem Management Plus (PM+), a WHO intervention. Then, those therapists will deliver PM+ (5 one-on-one skills-based sessions) to a total of 50 adult clients experiencing mild to moderate mental health difficulties (excluding anyone with cognitive difficulties or psychosis). Participants will complete (de-identified) self-report survey assessments before PM+, after PM+, 3 months later, and 6 months later. After receiving 5 sessions of PM+, participants will be randomized to either receive a one-time booster session of PM+ (to be co-created by the PI and the GBRC providers) three months later or to a control group which will receive a phone call reminding them that they will receive their third assessment soon.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Problem Management Plus booster session — A 60-minute session designed to refresh participants on the PM+ strategies (diaphragmatic breathing, problem management, behavioral activation, strengthening social support). Session consists of practicing strategies and developing plans for the future.

Primary Outcomes

  • Hospital Anxiety and Depression Scale (From enrollment, again at week5, again at week 18 and finally at week 30)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-10-16
Completion: 2026-07-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The New School
Principal Investigators:
  • Adam Brown D Brown, PhD (STUDY_CHAIR) - The New School
Contact Information
Study Contact:
Caroline McEneaney L McEneaney, JD, MA
12039521482
mcenc047@newschool.edu
Adam Brown D Brown, PhD
646-831-8657
brownad@newschool.edu
Felisha McBride McBride, PhD
242-602-5118
fmcbride85@gmail.com
Grand Bahama Resilience Center
Interventions
  • Behavioral: Problem Management Plus booster session — A 60-minute session designed to refresh participants on the PM+ strategies (diaphragmatic breathing, problem management, behavioral activation, strengthening social support). Session consists of practicing strategies and developing plans for the future.
Study Locations (1 sites)
Grand Bahama Resilience Center, Freeport, Grand Bahama The Bahamas
Eligibility Criteria
Inclusion Criteria: * Adults of 18 years or above * English-speaking * A score of \<91 on Global Assessment of Functioning * Located in the Bahamas Exclusion Criteria: * ● Imminent suicide risk (assessed at screening using Columbia Suicide-Severity Rating Scale, see document titled " Screener updated 10-30- 24") * Severe mental disorder (e.g. psychotic disorders) * Severe cognitive impairment (e.g. severe intellectual disability or dementia)
Conditions Post Stroke Depression
Phase NA
Enrollment 142
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

The study evaluates the effect of HBOT on depression in patients suffering from persistent symptoms of post stroke depression (PSD) in an double blind sham control study.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Device: hyperbaric oxygen therapy — The HBOT protocol consists of 60 daily sessions, five times per week, each session lasting 90 minutes. Investigational product: Multiplace hyperbaric oxygen chamber (Haux, Germany) located at the Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Israel.

Primary Outcomes

  • PSD symptoms (Change from Baseline immediately after the intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-11-08
Completion: 2030-12-01
Eligibility
Age: 50 Years – 85 Years
Sex: ALL
Volunteers: false
Enrollment: 142 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Assaf-Harofeh Medical Center
Principal Investigators:
  • Shai a Efrati, MD (PRINCIPAL_INVESTIGATOR) - Asaf-Harofhe MC
Contact Information
Study Contact:
Shai a Efrati, MD
972549212866
efratishai@outlook.com
Shai Efrati, Prof
972-8-9779393
efratishai@outlook.com
The Sagol Center for Hyperbaric Medicine and Research Shamir Medical Center (Assaf Harofeh)
Interventions
  • Device: hyperbaric oxygen therapy — The HBOT protocol consists of 60 daily sessions, five times per week, each session lasting 90 minutes. Investigational product: Multiplace hyperbaric oxygen chamber (Haux, Germany) located at the Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Israel.
Study Locations (1 sites)
The Sagol Center for Hyperbaric Medicine and Research Shamir Medical Center (Assaf Harofeh), Zrifin, 70300 Israel
Eligibility Criteria
Inclusion Criteria: 1. Age between 50 -85 2. Suffered an ischemic stroke 6 months to 7 years prior to their inclusion 3. Treated or being treated by antidepressants for at least 3 months 4. Diagnosis of PSD based on HDRS-17 score of 17 and above. 5. Stable psychological and pharmacological treatment for more than three months prior to inclusion. 6. Subject willing and able to read, understand and sign an informed consent. Exclusion Criteria: 1. Inability to attend scheduled clinic visits and/or comply with the study protocol 2. Diagnosis of a psychiatric disorder prior to the recent stroke including: major depression, schizophrenia or bipolar disease. 3. Diagnosis of aphasia or major cognitive decline 4. History of Deep brain stimulation (DBS) 5. History of traumatic brain injury, brain tumors, brain surgery, chronic subdural haemorrhages, Epilepsy 6. Active malignancy 7. Substance use at baseline. 8. History of other neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), Lewy body dementia (LBD), Frontotemporal dementia (FTD), Multiple sclerosis (MS), Amyotrophic lateral sclerosis (ALS), Creutzfeld Jacob disease (CJD), Multisystem atrophy (MSA), Pseudobulbar palsy (PSP), Corticobasal degeneration (CBD), Wernicke Korsakoff syndrome 9. Serious suicidal ideation 10. Renal or liver insufficiency, electrolyte imbalances 11. Chronic heart failure with ejection fraction of 30 or less 12. HBOT for any reason prior to study enrolment 13. Chest pathology incompatible with pressure changes (including active asthma or COPD) 14. Ear or Sinus pathology incompatible with pressure changes (above 3 otolaryngologist visits a year) 15. An inability to perform an awake brain MRI 16. No evidence of vascular related lesions in the brain MRI 17. Active smoking 18. Participation in another study
Conditions Depression, Depression During the Menopa...
Phase NA
Enrollment 120
Locations 1 sites
Compensation Compensation or reimbursement is mentioned in the public study record; confirm details with the study team.
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

\*\*Participants must live in San Diego County\*\* The purpose of this study is to learn more about an experimental Sleep \& Light Intervention (SALI) for menopausal mood changes or depression. Researchers want to find out whether adjusting the body's internal clock-which helps regulate sleep, hormones, mood, and energy- can improve symptoms such as depression, poor sleep, and low energy during menopause.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Phase Advanced Intervention (PAI) — Phase-advanced restricted sleep (i.e., sleep 9pm-1am only) for 1 night, followed by morning bright white light for 30 min/day for 2 weeks.
  • Behavioral: Phase Delay Intervention (PDI) — Phase-delayed restricted sleep (i.e., sleep 3am to 7am only) for 1 night, followed by evening bright white light for 30 min/day for 2 weeks.

Primary Outcomes

  • Urinary 6-sulfatoxymelatonin (6-SMT) (Urine is collected at baseline and after completing two-week intervention.)
  • Structured Interview Guide for the Hamilton Rating Depression Scale with Atypical Depression Supplement (SIGH-ADS) (Completed at baseline and after completing two-week intervention.)
  • Patient Health Questionnaire (PHQ-9) (Completed at baseline and after completing two-week intervention.)
  • Sleep Quality Rating (SQR) (Completed at baseline and after completing two-week intervention.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-03-11
Completion: 2029-02-28
Eligibility
Age: 45 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, San Diego
Principal Investigators:
  • Barbara Parry, M.D. (PRINCIPAL_INVESTIGATOR) - University of California, San Diego
Contact Information
Study Contact:
Jennifer A Perrott, MSW
(407) 619-9441
jperrott@health.ucsd.edu
David Sommerfeld, Ph.D.
(407) 966-7703
dsommerfeld@health.ucsd.edu
Barbara L Parry, M.D.
(619) 980-1942
bparry@ucsd.edu
University of California San Diego Hillcrest Medical Center
Interventions
  • Behavioral: Phase Advanced Intervention (PAI) — Phase-advanced restricted sleep (i.e., sleep 9pm-1am only) for 1 night, followed by morning bright white light for 30 min/day for 2 weeks.
  • Behavioral: Phase Delay Intervention (PDI) — Phase-delayed restricted sleep (i.e., sleep 3am to 7am only) for 1 night, followed by evening bright white light for 30 min/day for 2 weeks.
Study Locations (1 sites)
University of California San Diego Hillcrest Medical Center, San Diego, California 92103 United States
Eligibility Criteria
Inclusion Criteria: * Women aged 45-75 years old * Experiencing significant down, sad or hopeless feelings that are affecting their daily life * These mood changes started or got worse during the menopause transition * Irregular or no menstrual cycle for at least 6 months * Non-smoking * Located in San Diego County Exclusion Criteria: * Untreated sleep apnea * Migraine headaches that are triggered or worsened by bright light * Currently suicidal or psychotic * History of bipolar disorder * A medical condition or job where fatigue or changes in sleep schedule could be unsafe * Planning to start, stop, or change medications in the next 4 months
Conditions Healthy Volunteer, Major Depressive Diso...
Phase PHASE1
Enrollment 150
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

Background: Most medications that treat depression take weeks or months to work. Researchers want to develop fast-acting treatments. One dose of ketamine has a rapid antidepressant effect. For most people, this lasts a week or less. Repeated doses of ketamine may help maintain this effect. Objective: Main Study: To study the effects of ketamine in treating depression. Ketamine Metabolites Substudy: To study how ketamine effects brain chemistry. To study how ketamine effects the brain. This is done by looking at metabolites, which are created when a drug is broken down. Eligibility: Main Study: People ages 18-65 with major depressive disorder and healthy volunteers Ketamine Metabolites Substudy: Healthy volunteers ages 18-65 Design: Main Study: Participants will be screened in another study, with: * Medical and psychiatric history * Psychiatric and physical exam * Blood, urine, and heart tests Participants will be inpatients at NIH for 4 phases totaling 14-20 weeks. Phase I (2-7 weeks): * Gradually stop current medications * MRI: Participants lie and perform tasks in a machine that takes pictures of the body. * Mood and thinking tests * Blood and urine tests * Sleep test: Monitors on the skin record brain waves, breathing, heart rate, and movement during sleep. * Transcranial magnetic stimulation: A coil on the scalp gives an electrical current that affects brain activity. * Stress tests: Electrodes on the skin measure reactions to loud noises or electric shocks. Phase I tests are repeated in Phases II and III and in the final visit. Phase II (4-5 weeks): * 4 weekly IV infusions of ketamine or a placebo during an MRI or MEG. For the MEG, a cone over the head records brain activity. Phase III (optional): * 8 infusions of ketamine over 4 weeks Phase IV (optional): * Symptoms monitoring for 4 weeks * Participants will have a final visit. They will be offered standard treatment at NIH for up to 2 months. Ketamine Metabolites Substudy: Participants will be screened in another study, with: * Medical and psychiatric history * Psychiatric and physical exam * Blood, urine, and heart tests Participants will be inpatients at NIH for 4 days. Study Procedures: Mood and thinking tests Blood and urine tests 1 infusion of ketamine Spinal tap and spinal catheter: Used to get samples of cerebrospinal fluid (CSF). This is a fluid that moves around and within the brain and spinal cord. Studying CSF will help us learn how ketamine effects brain chemistry

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Ketamine — N-methyl-D-aspartate (NMDA) glutamate receptor (NMDA-R) antagonist
  • Other: Placebo — Placebo comparator
  • Device: Cobot TS MV robotic arm for TMS — TMS-Cobot TS MV \[Axilum Robotics\] robotic arm for spatial positioning and orientation of the TMS coil
  • Device: NeurOptics PLRTM-30000 Pupillometer — The Neu-rOptics PLRTM-3000 Pupillometer will use quantitative infrared technology to objectively and accurately measure pupil size and dynamics.

Primary Outcomes

  • To demonstrate more robust neuropharmacodynamic effects measured by neuropharmacodynamic imaging (fMRI+EEG and MEG) of ketamine 0.5 mg/kg as compared to placebo administered over 40 minutes. (Multiple)
  • Ketamine Metabolites Substudy: To determine if ketamine metabolites cross the blood brain barrier and enter the brain during ketamine IV administration. (Multiple)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2017-05-25
Completion: 2028-01-01
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: true
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Carlos A Zarate, M.D. (PRINCIPAL_INVESTIGATOR) - National Institute of Mental Health (NIMH)
Contact Information
Study Contact:
Adilah M Kirton
(301) 549-0315
adilah.meredith-kirton@nih.gov
NIH Clinical Center Office of Patient Recruitment (OPR)
800-411-1222
ccopr@nih.gov
National Institutes of Health Clinical Center
Interventions
  • Drug: Ketamine — N-methyl-D-aspartate (NMDA) glutamate receptor (NMDA-R) antagonist
  • Other: Placebo — Placebo comparator
  • Device: Cobot TS MV robotic arm for TMS — TMS-Cobot TS MV \[Axilum Robotics\] robotic arm for spatial positioning and orientation of the TMS coil
  • Device: NeurOptics PLRTM-30000 Pupillometer — The Neu-rOptics PLRTM-3000 Pupillometer will use quantitative infrared technology to objectively and accurately measure pupil size and dynamics.
Study Locations (1 sites)
National Institutes of Health Clinical Center, Bethesda, Maryland 20892 United States
Eligibility Criteria
* INCLUSION CRITERIA: Inclusion Criteria: All Subjects (Main Study) 1. 18 to 65 years of age. 2. Each subject must have a level of understanding sufficient to agree to all required tests and examinations and sign an informed consent document. 3. All subjects must have undergone a screening assessment under either protocol 01-M-0254, "The Evaluation of Patients with Mood and Anxiety Disorders and Healthy Volunteers" or protocol 17-M-0181 ("Recruitment and Characterization of Research Volunteers for NIMH Intramural Studies"). 4. Agree to be hospitalized Additional Inclusion Criteria: Patients with MDD (Main Study) 1. At the initial study enrollment, subjects must have fulfilled DSM-IV or DSM-5 criteria for Major Depression, single episode or recurrent. Subjects must be experiencing a current major depressive episode of at least 2 weeks duration. 2. At the initial screening and beginning of Phases II and III, subjects must have a baseline score on the MADRS \>= 20 and YMRS of \< 12. 3. Current or past history of lack of response to one adequate antidepressant trial, operationally defined using the Antidepressant Treatment History Form (ATHF); a failed adequate trial of ECT would count as an adequate antidepressant trial. Ketamine Metabolites Substudy Inclusion Criteria: Healthy Volunteers 1. 18 to 65 years of age. 2. Each subject must have a level of understanding sufficient to agree to all required tests and examinations and sign an informed consent document. 3. All subjects must have undergone a screening assessment under either protocol 01-M-0254 "The Evaluation of Patients with Mood and Anxiety Disorders and Healthy Volunteers") or 17-M-0181 ("Recruitment and Characterization of Research Volunteers for NIMH Intramural Studies"). 4. Agree to be hospitalized. EXCLUSION CRITERIA: Additional Exclusion Criteria: Patients with MDD (Main Study) 1. Current diagnosis of Bipolar Disorder including Bipolar I, Bipolar II, or Bipolar NOS diagnoses. 2. Current psychotic features or a diagnosis of Schizophrenia or any other psychotic disorder as defined in the DSM-IV or DSM-5. 3. Subjects with a history of DSM-IV or DSM-5 drug or alcohol dependency or abuse (except for caffeine or nicotine dependence) within the preceding 3 months. In addition, subjects who currently are using drugs (except for caffeine or nicotine) must not have used illicit substances or known drugs of abuse in the 2 weeks prior to screen and must have a negative alcohol and drug urine test (except for prescribed benzodiazepines or stimulants) urine test at screening. 4. Treatment with a reversible MAOI within two weeks prior to Phase II. 5. Subjects who, in the investigator s judgment, pose a current serious suicidal or homicidal risk. Exclusion Criteria: All Subjects (Main Study) 1. Pregnant or nursing women or women who plan to become pregnant. Women who are able to get pregnant must be willing to use at least one form of effective birth control during the entire period of study participation (or until last clinical labs and rating) and have a negative pregnancy test that was obtained no more than 24 hours prior to MRI and infusion of ketamine. 2. Serious, unstable illnesses including hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease, coronary artery disease, atherosclerotic ischemic stroke, and atrial fibrillation), endocrinologic, neurologic, immunologic, or hematologic disease. 3. Clinically significant abnormal laboratory tests. 4. Subjects with one or more seizures without a clear and resolved etiology or current use of medication known to lower seizure threshold. History of seizure (regardless of age or etiology), history of epilepsy in self or first-degree relatives, stroke, brain surgery, head injury, or known structural brain lesion will be excluded from the TMS procedures. 5. Treatment with any other concomitant medication 14 days prior to Phase II. An exception of this would be necessary for those who are taking Fluoxetine or Aripiprazole. Prior to Phase II, treatment with Fluoxetine must be discontinued for at least 5 weeks and treatment with Aripiprazole must be discontinued for at least 3 weeks. 6. Any use of opioid medication in the past 3 months 7. Presence of metallic (ferromagnetic) implants (e.g, heart pacemaker, aneurysm clip) (for subjects doing imaging component of the study only). 8. Presence of any medical illness likely to alter brain morphology and/or physiology (e.g., hypertension, diabetes) even if controlled by medications. 9. Subjects who have hearing loss that has been clinically evaluated and diagnosed 10. Participants who are uncomfortable in small closed spaces (have claustrophobia), unable to lie comfortably supine for up to 90 minutes, and would feel uncomfortable in the MRI machine (for subjects doing imaging component of the study only). 11. Positive HIV test 12. Weight \> 119 kg 13. \[for participants undergoing NPU Threat Test with Auditory Startle\] Known history of hearing loss Additional Exclusion Criteria: Healthy Volunteers (Main Study) 1\. Current or past history of any DSM-IV or DSM-5 Axis I disorder based on clinical assessment and confirmed by a structured diagnostic interview (SCID). Ketamine Metabolites Substudy Exclusion Criteria: Healthy Volunteers 1. Current or past history of any DSM-IV or DSM-5 Axis I disorder based on clinical assessment and confirmed by a structured diagnostic interview (SCID). 2. Current (within the past 3 months) or past alcohol or substance abuse or dependence diagnosis (except for nicotine or caffeine) 3. Pregnant or nursing women or women who plan to become pregnant. Women who are able to get pregnant must be willing to use at least one form of effective birth control during the 4-days of the study participation (or until last clinical labs and rating) and have a negative pregnancy test that was obtained no more than 24 hours prior to infusion of ketamine. 4. Serious, unstable illnesses including hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease, coronary artery disease, atherosclerotic ischemic stroke, and atrial fibrillation), endocrinologic, neurologic, immunologic, or hematologic disease. 5. Clinically significant abnormal laboratory tests. 6. Subjects with one or more seizures without a clear and resolved etiology or current use of medication known to lower seizure threshold. 7. Treatment with any other concomitant medication. 8. Any use of opioid medication in the past 3 months 9. Positive HIV test 10. Weight \> 119 kg 11. Presence of metallic (ferromagnetic) implants (e.g, heart pacemaker, aneurysm clip) (for subjects doing neuroimaging component of the study only). 12. Participants who are uncomfortable in small closed spaces (have claustrophobia), unable to lie comfortably supine for up to 90 minutes, and would feel uncomfortable in the MRI machine (for subjects requiring clinical MRI scans for safety and/or structural MRI scans for MEG coregistration).
Conditions Bipolar Depression
Phase NA
Enrollment 160
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this study was to explore the efficacy and safety of temporal interference stimulation to improve bipolar depression, as well as to explore the corresponding neuroimaging mechanisms using magnetic resonance and electroencephalogram to provide novel intervention protocols and objective indicators of efficacy prediction for depressive episodes in bipolar disorder.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Device: Temporal Interference Stimulation — A non-invasive, non-invasive method of deep brain electrical stimulation utilizing high-frequency electric field interactions to produce a low-frequency envelope to modulate neural activity.
  • Device: Sham Temporal Interference Stimulation — The same machine was used as the temporal Interferenc real stimulus, with current creep only 20 seconds before stimulus onset to simulate the real stimulus sensation.

Primary Outcomes

  • Montgomery-Asberg Depression Rating Scale(MADRS) (* "Baseline" * "Day 5" * "2 weeks after the end of temporal interference stimulation" * "4 weeks after the end of temporal interference stimulation")
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-20
Completion: 2026-12
Eligibility
Age: 18 Years – 45 Years
Sex: ALL
Volunteers: false
Enrollment: 160 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: First Affiliated Hospital of Zhejiang University
Contact Information
Study Contact:
Shaohua Hu, PhD
0571-87232984
dorhushaohua@zju.edu.cn
Hu ShaoHua
0571-87232984
dorhushaohua@zju.edu.cn
Department of Psychiatry, First Affiliated Hospital of Zhejiang University
Interventions
  • Device: Temporal Interference Stimulation — A non-invasive, non-invasive method of deep brain electrical stimulation utilizing high-frequency electric field interactions to produce a low-frequency envelope to modulate neural activity.
  • Device: Sham Temporal Interference Stimulation — The same machine was used as the temporal Interferenc real stimulus, with current creep only 20 seconds before stimulus onset to simulate the real stimulus sensation.
Study Locations (1 sites)
Department of Psychiatry, First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang 310000 China
Eligibility Criteria
Inclusion Criteria: * right-handed, and have completed nine years of compulsory education; * Meet the diagnostic criteria for bipolar depression in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5); * ≥18 points on the Hamilton Depression Inventory (HAMD- 17); * ≤8 points on the Young's Mania Rating Scale (YMRS); * Subjects who have not been treated with psychiatric medication, or those who have been treated with medication are required to undergo medication washout within 2 weeks before randomization; * Subjects/legal guardians are willing to cooperate with the treatment and sign an informed consent form after they have fully understood the Temporal Interference Stimulation (TI). Exclusion Criteria: * Contraindications to magnetic resonance scanning (MRI) or time-interference stimulation (TI), such as the presence of metallic or electronic devices in the body (intracranial metallic foreign bodies, cochlear implants, pacemakers and stents, and other metallic foreign bodies); * Prior or current electroconvulsive therapy (ECT), modified electroconvulsive therapy (MECT), transcranial magnetic stimulation (TMS), transcranial direct current therapy (tDCS), transcranial alternating current stimulation (tACS), or other neurostimulation; * Pregnant and lactating women, and women of childbearing age with a positive urine pregnancy; * Possesses a diagnosis of another major psychiatric disorder that has been assessed by the study investigator as a major disorder that results in more impairment than a diagnosis of bipolar disorder; * Co-morbid other psychiatric disorders, including obsessive-compulsive disorder, personality disorders, anxiety spectrum disorders, mental retardation, substance dependence (abuse), etc.; Has active suicidal ideation (≥ 4 points on item 10 of the MADRS); * Risk of serious injury to self or others; * History of serious physical illness or disease that may affect the central nervous system; * Risk of neurologic disorders or seizures, such as previous craniosynostosis, cranial trauma, abnormal electroencephalograms, magnetic resonance evidence of structural abnormalities of the brain, or family history of epilepsy.
Conditions Bipolar Depression Depressed Phase
Phase PHASE3
Enrollment 80
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this trial is to conduct an adequately powered clinical trial of once daily LFR for individuals diagnosed with treatment-resistant BD-DE who have not responded to iTBS or sham treatment applied to the left DLPFC. This work will develop the evidence supporting the use of LFR rTMS for individuals with treatment-resistant BD-DE who currently have limited treatment options to alleviate their suffering. Participants will come for 30 days of LFR, with a 6-week follow-up period. Symptoms of depression (for determining treatment efficacy) and mania (for determining treatment safety) will be assessed using the 17-item Hamilton Rating Scale for Depression (HRSD-17) and the Young Mania Rating Scale (YMRS) every five treatments during the treatment course, and at 1 week and 6 week after treatment completion.

Design

Study type: Interventional Phases: Phase3 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: MagPro X100/R30 stimulator, Cool-B70 coil — 1Hz rTMS delivered to the right DLPFC

Primary Outcomes

  • Change on the 17-item Hamilton Rating Scale for Depression (HRSD-17) (6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-05-27
Completion: 2030-05
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tyler Kaster
Collaborators: The Poul Hansen Family Centre for Depression, Toronto Western Hospital, Canada, University Health Network, Toronto
Principal Investigators:
  • Tyler Kaster (PRINCIPAL_INVESTIGATOR) - CAMH
Contact Information
Study Contact:
Hannah Taalman
416-535-8501
Hannah.taalman@camh.ca
Mawahib Semeralul
416-535-8501
mawahib.semeralul@camh.ca
Eileen Lam
437-553-0367
Eileen.lam@uhn.ca
University Health Network Toronto Western Hospital
Interventions
  • Device: MagPro X100/R30 stimulator, Cool-B70 coil — 1Hz rTMS delivered to the right DLPFC
Study Locations (2 sites)
University Health Network Toronto Western Hospital, Toronto, Ontario M5T 2S8 Canada
Centre For Addiction and Mental Health (CAMH), Toronto, Ontario M6J 1H1 Canada
Eligibility Criteria
Inclusion Criteria: 1. Must be deemed to have capacity to provide informed consent; 2. Must be an outpatient; 3. Have a DSM 5 diagnosis of bipolar disorder (type I or II), current episode depressed confirmed by Mini-International Neuropsychiatric Interview version 7.0.2 (MINI) assessed during TRIBE trial participation with no contradictory evidence that the current episode is depressed from FLARE trial screening assessments (YMRS\>10/PHQ-9 \<10); 4. older than 18 years; 5. failure to achieve a clinical response within the TRIBE study (CTO#: 4343) defined as ≤50% response from baseline to 6 weeks on the HRSD-17. 6. Score ≥10 on PHQ-9 at both (i) the 6 weeks follow-up in the TRIBE trial and (ii) at screening; 7. ≤3 months from completion of the TRIBE study; 8. not currently experiencing a mixed or manic episode (YMRS ≤10); 9. no increase or initiation of psychotropic medication with intention of treating depressive symptoms in the 4 weeks prior to screening. This excludes targeted treatment of insomnia with trazodone, melatonin, low-dose doxepin \[3-6mg\], low-dose benzodiazepines \[≤2mg lorazepam daily equivalent\], non-benzodiazepine benzodiazepine receptor agonists, or orexin antagonists; 10. currently receiving treatment with one of the following non-anticonvulsant mood stabilizer with evidence for prevention of mania: lithium, quetiapine, asenapine, aripiprazole, paliperidone (\>6mg), risperidone, olanzapine, ziprasidone, haloperidol, clozapine (lurasidone and cariprazine are excluded due to lack of evidence for preventing mania); 11. able to adhere to the treatment schedule; 12. pass the TMS adult safety screening questionnaire. Exclusion Criteria: 1. have a history of MINI diagnosis of a substance use disorder (other than nicotine and/or caffeine) within the last 3 months; 2. have a concomitant major unstable medical illness; 3. have active suicidal intent; 4. are pregnant or intend to get pregnant during the study; 5. have a lifetime MINI diagnosis of schizophrenia or schizoaffective disorder; 6. have psychotic symptoms within the current episode; 7. have a MINI anxiety disorder, trauma-related disorder, obsessive compulsive disorder, or personality disorder assessed by a study investigator to be primary and/or causing greater impairment than BD-DE; 8. failure of an adequate acute course of ECT as defined by ATHF-SF during the current episode; 9. have any clinically significant neurological disorder (e.g., recent major cerebrovascular accident), or any history of seizure except those therapeutically induced by ECT or with clear precipitant (e.g., febrile seizure of childhood, alcohol withdrawal, etc.); 10. have any intracranial implant (e.g., aneurysm clips, shunts, stimulators,) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed; 11. if participating in psychotherapy, must have been in stable treatment for at least 3 months prior to entry into the study, with no anticipation of change in the frequency of therapeutic sessions, or the therapeutic focus over the duration of the study; 12. have a clinically significant laboratory abnormality, in the opinion of the one of the principal investigators; 13. are currently taking lorazepam ≥2 mg daily (or equivalent) due to the potential to limit rTMS efficacy; 14. are currently taking, any dose of an anticonvulsant due to the potential to limit rTMS efficacy; 15. if anticonvulsants have been discontinued prior to screening, at least 5 half-lives have elapsed until screening to allow sufficient drug clearance; 16. have a non-correctable clinically significant sensory impairment (i.e., cannot hear well enough to cooperate with interview). 17. participant was withdrawn from the TRIBE study due to safety concerns or at the discretion of the PI. 18. any history of substance use in the last 4 weeks which poses a safety concern to undergo rTMS as assessed by the PI's review of responses to the trial's 'Substance Use Screening Questions Form'.
Conditions Major Depressive Disorder
Phase NA
Enrollment 120
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this research study is to determine if application of near infrared energy to the forehead can change blood flow in the brains of people with depression. Near infrared energy is like light but is not visible to the human eye.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Diagnostic Masking/blinding: Double

Interventions / Regimen

  • Device: Transcranial Photobiomodulator — Transcranial photobiomodulator delivers Near-Infrared Radiation (NIR) continuous middle irradiance (291.7 mW/cm2) to patients' foreheads.
  • Device: Sham — Transcranial Photobiomodulator delivers sham irradiance odes of 0 mW/cm2

Primary Outcomes

  • Percent change of cerebral blood flow (CBF) (Baseline, Visit 18 (Week 10))
  • Change in the Montgomery-Asberg Depression Rating Scale (MADRS) score (Baseline, Visit 17 (Week 9, endpoint))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-04-01
Completion: 2026-06-30
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: NYU Langone Health
Collaborators: National Institutes of Health (NIH)
Principal Investigators:
  • Dan Iosifescu, MD (PRINCIPAL_INVESTIGATOR) - NYU Langone Health
Contact Information
Study Contact:
Dan Iosifescu, MD
646-754-5156
Dan.Iosifescu@nyulangone.org
Anna Peterson
646-754-2260
Anna.Peterson@nyulangone.org
Paolo Cassano, MD,PhD
617-726-6421
PCASSANO@mgh.harvard.edu
Harvard Medical School
Interventions
  • Device: Transcranial Photobiomodulator — Transcranial photobiomodulator delivers Near-Infrared Radiation (NIR) continuous middle irradiance (291.7 mW/cm2) to patients' foreheads.
  • Device: Sham — Transcranial Photobiomodulator delivers sham irradiance odes of 0 mW/cm2
Study Locations (3 sites)
Harvard Medical School, Boston, Massachusetts 02114 United States
NYU Langone Health, New York, New York 10016 United States
Nathan Kline Institute for Psychiatric Research, Orangeburg, New York 10962 United States
Eligibility Criteria
Inclusion Criteria: * Participants must be able to give written informed consent and follow study procedures * Participants must be 18-65 years of age * Participants must have major depressive disorder; all the following conditions need to be met to ensure presence of significant depression symptoms: 1. Meeting diagnostic criteria for Major Depressive Disorder (MDD) in the past two weeks, at the DSM-5 Mini-International Neuropsychiatric Interview (MINI) 2. Inventory for Depressive Symptomatology Clinician-rated (IDS-C) total score ≥23 at screening 3. Depression symptoms are the primary target of treatment or treatment-seeking. * Women of child-bearing potential must agree to use adequate contraception * Participants taking medications or psychotherapy approved for the treatment of major depressive disorder will need to be stable for at least 8 weeks prior to screen. Exclusion Criteria: * Unwilling or unable to comply with study requirements * Patients judged to be at serious and imminent suicidal (C-SSRS≥4) or homicide risk, or currently in crisis such that inpatient hospitalization or other crisis management should take priority. * History of any or psychotic or bipolar disorder * Met diagnostic criteria for an alcohol or substance use disorder, post-traumatic stress disorder, obsessive-compulsive disorder, anorexia nervosa, or bulimia nervosa within the preceding 6 months * History of dementia, traumatic brain injury (TBI), or neurological disorders affecting the brain, including any history of stroke or seizure disorders requiring treatment in the last 5 years * Cognitive impairment significant as determined by the Montreal Cognitive Assessment (MOCA) \<22 or MOCA-Blind \<19. * History of antisocial personality disorder, or any clinically significant personality trait that would, in the investigator's judgment, preclude safe study participation or impair ability to remain adherent with the treatment protocol * History of significant treatment non-adherence or situations where the subjects are unlikely to adhere to treatment, in the opinion of the investigator. * Pregnant (as confirmed by pregnancy test at screen) or nursing * Currently undergoing device-based treatment for depression or taking medications for depression other than SSRIs, SNRIs, or Wellbutrin (bupropion). * Treatment resistance with failure to respond to more than two adequate treatments with FDA-approved antidepressant medications during current episode of major depressive disorder. * History of ECT in the last 12 months; lifetime history of VNS; lifetime treatment resistance to any FDA-approved device-based treatment for major depressive disorder (such as ECT, TMS, VNS); device-based interventions for depression will need to be discontinued at least 8 weeks prior to screen. * Serious, unstable medical illnesses including hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, neurologic, immunologic, hematologic disease; defined as any medical illness which is not well-controlled with standard-of-care v Clinically significant abnormal findings of laboratory parameters including urine toxicology screen for drugs of abuse or at physical examination. * Clinical or laboratory evidence of uncontrolled hypothyroidism; if maintained on thyroid medication must be euthyroid for at least 1 month before screening. * Past intolerance or hypersensitivity to tPBM. * Significant skin conditions (i.e., hemangioma, scleroderma, psoriasis, rash, open wound or tattoo) on the subject's scalp that are found in the area of the procedure sites. * Any use of light-activated drugs (photodynamic therapy) within 14 days prior to study enrollment. * Any type of implants in the head, whose functioning might be affected by tPBM (e.g., stent, clipped aneurysm, embolized AVM, implantable shunt - Hakim valve). * Failure to meet standard MRI safety requirements (e.g., claustrophobia, non-removable piercings, implanted medical devices, other non-removable metals) as determined by the MRI Safety Checklist.